Effect of absolute monocyte count post-transplant on the outcome of patients with acute myeloid leukemia undergoing myeloablative allogeneic hematopoietic stem cell transplant with busulfan and cyclophosphamide conditioning

•High AMC on PTD 15 is associated with improved platelet engraftment.•AMC on PTD 15 has no impact on CIR and non-relapse mortality.•Patients with a high AMC on PTD 15 have a worse OS and post-relapse survival. Peripheral monocytes have recently been evaluated as a prognostic factor in different type...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2018-06, Vol.69, p.60-65
Main Authors: Tang, Liyuan, Wang, Na, Xing, Chongyun, Zhuang, Qiang, Liang, Bin, Sun, Lan, Chen, Yi, Qian, Yan, Shen, Zhijian, Jiang, Songfu, Yu, Kang, Feng, Jianhua
Format: Article
Language:English
Subjects:
Absolute monocyte count
Acute myeloid leukemia
Myeloablative allogeneic hematopoietic stem cell transplant
Prognosis
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•High AMC on PTD 15 is associated with improved platelet engraftment.•AMC on PTD 15 has no impact on CIR and non-relapse mortality.•Patients with a high AMC on PTD 15 have a worse OS and post-relapse survival. Peripheral monocytes have recently been evaluated as a prognostic factor in different types of hematological malignancies. This study assessed the prognostic value of absolute monocyte count (AMC) post-transplant on the clinical outcomes of 59 patients with acute myeloid leukemia (AML) who had undergone myeloablative conditioning (MAC) allogeneic hematopoietic stem cell transplant (allo-HSCT) with busulfan and cyclophosphamide (Bu/Cy). Kaplan-Meier analysis showed that patients with a high AMC (≥ 0.57 × 109/L) on post-transplant day (PTD) 15 had a significantly worse overall survival (OS) compared to patients with a low AMC (
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2018.04.006